Peel Hunt Reaffirms “Buy” Rating for Motif Bio (MTFB)

Peel Hunt reiterated their buy rating on shares of Motif Bio (LON:MTFB) in a research report released on Wednesday, January 10th. The brokerage currently has a GBX 107 ($1.50) price target on the stock.

Other analysts have also recently issued research reports about the stock. FinnCap reaffirmed a buy rating and set a GBX 100 ($1.40) price objective on shares of Motif Bio in a research note on Thursday, November 16th. Beaufort Securities reissued a speculative buy rating and issued a GBX 110 ($1.54) price target on shares of Motif Bio in a research note on Thursday, November 16th. Finally, Northland Securities reissued a buy rating on shares of Motif Bio in a research note on Friday, January 5th.

Shares of Motif Bio (LON MTFB) traded down GBX 0.62 ($0.01) during midday trading on Wednesday, reaching GBX 35.38 ($0.50). 632,977 shares of the company traded hands, compared to its average volume of 749,689. Motif Bio has a one year low of GBX 22.50 ($0.32) and a one year high of GBX 51.75 ($0.73). The stock has a market cap of $92.79 and a PE ratio of -141.50.

WARNING: “Peel Hunt Reaffirms “Buy” Rating for Motif Bio (MTFB)” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/05/motif-bios-mtfb-buy-rating-reaffirmed-at-peel-hunt-2.html.

About Motif Bio

Motif Bio plc is a clinical-stage biopharmaceutical company. The Company is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It operates in the development and commercialization of pharmaceutical formulations segment. The Company is focused on development of its product, Iclaprim, for the treatment of the bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumonia (MDRSP).

Receive News & Ratings for Motif Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply